Smartest Doc
CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin
Journal of Clinical Pharmacy and Therapeutics, 08/10/2012
Clinical Article
Jiang XY et al. – CYP7A1 gene polymorphism influences the LDL–lowering effects of atorvastatin in Chinese Hans. If replicated by others, identification of the tagged functional variant would be needed.
Methods- One hundred and seven unrelated Chinese Han hypercholesterolemia patients were recruited from among the inpatients and outpatients of Tangshan Gongren Hospital of Hebei, China.
- Three polymorphisms of the CYP3A5 gene, seven polymorphisms of the CYP7A1 gene and seven polymorphisms of the ABCG8 gene were selected using a tagging single–nucleotide polymorphism (tSNP) strategy and genotyped using Snapshot platform.
- SNP rs8192870, located in the first intron of the CYP7A1 gene, was associated with the LDL level lowering response to atorvastatin.
- The LDL levels were reduced by 27.89% for the GG/GA genotype carriers and 35.26% for the AA genotype carriers, respectively, after atorvastatin treatment (P = 0.021).
- The significance remained after adjusting for covariates.
- In addition, the authors observed that rs4148222 in the 11th intron of the ABCG8 gene significantly associated with the baseline levels of HDL (P = 0.046).